Price
Financials
Standalone, Rs crore| Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.80 | 43.25 | 45.24 | 48.57 | 48.89 | 45.37 | 44.36 | 49.77 | 37.84 | 55.16 | 57.75 | 44.23 |
| Expenses | 31.81 | 38.60 | 38.72 | 42.11 | 42.27 | 38.52 | 38.01 | 43.40 | 36.99 | 44.46 | 47.46 | 40.72 |
| Operating Profit | 3.99 | 4.65 | 6.52 | 6.46 | 6.62 | 6.85 | 6.35 | 6.37 | 0.85 | 10.70 | 10.29 | 3.51 |
| OPM % | 11.15% | 10.75% | 14.41% | 13.30% | 13.54% | 15.10% | 14.31% | 12.80% | 2.25% | 19.40% | 17.82% | 7.94% |
| Other Income | 0.38 | 0.64 | 1.01 | 2.08 | 0.66 | 0.47 | 0.56 | 1.13 | 0.72 | 0.85 | 2.09 | 0.79 |
| Interest | 0.04 | 0.04 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Depreciation | 2.83 | 2.88 | 2.91 | 2.89 | 2.76 | 2.82 | 2.85 | 2.80 | 2.66 | 2.69 | 2.91 | 2.49 |
| Profit before tax | 1.50 | 2.37 | 4.57 | 5.61 | 4.49 | 4.47 | 4.03 | 4.68 | -1.11 | 8.84 | 9.46 | 1.80 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 1.50 | 2.37 | 4.56 | 5.61 | 4.49 | 4.48 | 4.02 | 4.68 | -1.11 | 8.85 | 9.47 | 1.81 |
| EPS in Rs | 0.13 | 0.20 | 0.38 | 0.47 | 0.38 | 0.38 | 0.34 | 0.39 | -0.09 | 0.74 | 0.80 | 0.15 |
| Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 9m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 496 | 606 | 785 | 1,060 | 1,314 | 834 | 253 | 171 | 173 | 188 | 195 |
| Expenses | 381 | 445 | 535 | 690 | 939 | 1,157 | 868 | 387 | 145 | 151 | 162 | 170 |
| Operating Profit | 39 | 52 | 71 | 95 | 120 | 157 | -34 | -134 | 26 | 22 | 26 | 25 |
| OPM % | 9% | 10% | 12% | 12% | 11% | 12% | -4.1% | -53% | 15% | 13% | 14% | 13% |
| Other Income | 2 | -0 | 1 | 1 | 1 | 2 | -74 | -69 | -72 | 4 | 3 | 4 |
| Interest | 14 | 21 | 27 | 34 | 43 | 59 | 94 | 71 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 6 | 8 | 9 | 12 | 15 | 19 | 15 | 11 | 12 | 11 | 11 |
| Profit before tax | 22 | 24 | 36 | 53 | 66 | 85 | -221 | -289 | -56 | 14 | 18 | 19 |
| Tax % | 16% | 22% | 15% | 22% | 20% | 18% | 2% | 3% | 0% | 0% | 0% | 0% |
| Net Profit | 19 | 19 | 31 | 42 | 53 | 70 | -226 | -299 | -56 | 14 | 18 | 19 |
| EPS in Rs | 1.76 | 1.77 | 2.95 | 3.94 | 5.01 | 6.59 | -18.99 | -25.16 | -4.75 | 1.18 | 1.49 | 1.60 |
| Dividend Payout % | 7% | 8% | 6% | 5% | 3% | 5% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -13% | % | 4% | 4% | ||
| Compounded Profit Growth | -8% | % | 4% | 8% | ||
| Stock Price CAGR | -11% | % | % | % | ||
| Return on Equity | % | % | % | % |
| Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 21 | 24 | 24 | 24 | 1 | 1 | 1 |
| Reserves | 96 | 112 | 188 | 182 | 233 | 323 | 94 | -205 | -664 | -627 | -610 | -592 |
| Borrowings | 262 | 343 | 344 | 508 | 644 | 725 | 824 | 836 | 828 | 828 | 828 | 828 |
| Other Liabilities | 29 | 35 | 44 | 74 | 84 | 92 | 69 | 68 | 88 | 88 | 80 | 76 |
| Total Liabilities | 397 | 501 | 586 | 774 | 972 | 1,162 | 1,012 | 723 | 276 | 290 | 299 | 313 |
| Fixed Assets | 56 | 184 | 181 | 201 | 272 | 325 | 332 | 319 | 149 | 141 | 135 | 128 |
| CWIP | 107 | 23 | 27 | 60 | 43 | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 4 | 4 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 233 | 290 | 374 | 509 | 654 | 820 | 678 | 404 | 128 | 149 | 164 | 185 |
| Total Assets | 397 | 501 | 586 | 774 | 972 | 1,162 | 1,012 | 723 | 276 | 290 | 299 | 313 |
| Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -50 | -28 | -36 | -53 | -70 | -69 | -82 | -28 | 35 | 4 | 23 | 41 |
| Cash from Investing Activity | -66 | -51 | -8 | -61 | -64 | -27 | -10 | 0 | -7 | -4 | -3 | -3 |
| Cash from Financing Activity | 47 | 78 | 46 | 117 | 134 | 103 | 96 | 22 | 0 | 0 | 0 | 0 |
| Net Cash Flow | -69 | -1 | 1 | 2 | -0 | 6 | 4 | -6 | 28 | 0 | 20 | 38 |
| Free Cash Flow | -121 | -78 | -46 | -115 | -135 | -101 | -93 | -30 | 27 | -0 | 18 | 36 |
| CFO/OP | -129% | -55% | -51% | -56% | -58% | -44% | 238% | 21% | 133% | 19% | 86% | 160% |
| Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 117 | 116 | 121 | 122 | 115 | 138 | 264 | 47 | 62 | 52 | 49 |
| Inventory Days | 90 | 102 | 112 | 109 | 105 | 106 | 136 | 198 | 173 | 209 | 162 | 149 |
| Days Payable | 23 | 23 | 23 | 28 | 24 | 20 | 23 | 44 | 214 | 183 | 167 | 155 |
| Cash Conversion Cycle | 183 | 195 | 205 | 202 | 203 | 201 | 251 | 418 | 7 | 88 | 48 | 43 |
| Working Capital Days | 176 | 188 | 72 | 78 | 72 | 79 | 129 | 68 | -566 | -514 | -464 | -474 |
| ROCE % | 11% | 11% | 13% | 14% | 14% | 15% | -5% | -17% | 7% | 8% | 8% |
| Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 32.53% | 32.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.01% | 0.01% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 67.46% | 67.46% | 99.97% | 99.97% | 99.98% | 99.97% | 99.97% | 99.97% | 99.97% | 99.99% | 99.99% | 99.98% |
| No. of Shareholders | 24,836 | 24,830 | 24,854 | 24,854 | 24,854 | 24,854 | 24,854 | 24,854 | 24,853 | 24,837 | 24,837 | 24,837 |
Fundamentals
Market Cap₹ 39.2 Cr.
Current Price₹ 3.30
Stock P/E2.06
Book Value₹ -49.6
ROCE8.36 %
ROE%
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)8%
Standalone figures.
Valuation
Market capRs 39 Cr
Enterprise valueRs 777 Cr
P/E (TTM)2.06x
Price to book-0.07x
Price to sales0.20x
EV / EBITDA26.07x
EV / EBIT40.79x
EV / sales3.98x
Price to cash flow0.95x
Earnings yield48.46%
P/B, 5-year average-0.72x
Profitability
Operating margin (excl. other income)13.00%
Operating margin (incl. other income)15.29%
EBITDA margin15.28%
Pre-tax margin9.74%
Net profit margin9.75%
Net margin, latest quarter4.09%
ROE-3.17%
ROCE8.36%
ROA6.21%
ROE, 3-year average-2.75%
ROCE, 3-year average8.03%
ROA, 3-year average5.72%
ROE, 5-year average189.84%
ROCE, 5-year average-3.32%
ROA, 5-year average-5.73%
ROIC (approx.)12.93%
Other income / net worth-0.76%
Growth
Sales growth (latest year)3.50%
Profit growth (latest year)7.58%
Sales CAGR, 3 years4.43%
Sales CAGR, 5 years-25.22%
Sales growth QoQ-23.41%
Profit growth QoQ-80.89%
Sales growth YoY (latest quarter)-11.13%
Profit growth YoY (latest quarter)-61.32%
Per share
EPS (TTM)Rs 1.60
EPS (latest quarter)Rs 0.15
EPS, 5-year averageRs -25.16
Book value per shareRs -49.63
Sales per shareRs 16.39
Cash flow per shareRs 3.46
Free cash flow per shareRs 3.03
Efficiency
Asset turnover0.62x
Fixed asset turnover1.52x
Inventory turnover2.44x
Inventory days149 days
Debtor days49 days
Debtors turnover7.48x
Creditor days155 days
Cash conversion cycle43 days
Working capital days-474 days
Leverage
Total debtRs 828 Cr
Cash and bankRs 90 Cr
Net debtRs 738 Cr
Debt to equity-1.40x
Net debt / EBITDA24.76x
Interest coverage317.50x
Owners' fund to total sources-188.59%
Debt to assets264.41%
Cash flow
Cash from Operating Activity (latest year)Rs 41 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Net Cash Flow (latest year)Rs 38 Cr
Free cash flow (latest year)Rs 36 Cr
FCFE (approx.: FCF + change in debt)Rs 36 Cr
Sales to cash flow4.74x
Statement figures
Net sales (TTM)Rs 195 Cr
Net sales (latest year)Rs 195 Cr
Sales (latest quarter)Rs 44 Cr
Operating profit excl. other income (latest year)Rs 25 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 4 Cr
EBITDA (TTM)Rs 30 Cr
PBDT (TTM)Rs 30 Cr
Profit before tax (TTM)Rs 19 Cr
Net profit (TTM)Rs 19 Cr
Net profit (latest year)Rs 19 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 11 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 95 Cr
Total expenditure (latest year)Rs 170 Cr
Total income (latest year)Rs 199 Cr
Share capitalRs 1 Cr
ReservesRs -592 Cr
Shareholders' fundsRs -590 Cr
Total assetsRs 313 Cr
Net blockRs 128 Cr
Capital work in progressRs 0 Cr
ReceivablesRs 26 Cr
InventoryRs 39 Cr
Other liabilitiesRs 76 Cr
Shares outstanding (crore)11.89
Ownership
Promoter holding0.00% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SHARONBIO | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -18.5% | -2.8% | -15.7 pts |
| 1 month | -2.9% | -6.8% | +3.9 pts |
| 3 months | -34.7% | -7.6% | -27.0 pts |
| 6 months | -40.5% | +0.4% | -40.9 pts |
| 1 year | -40.5% | -9.9% | -30.6 pts |
| 2 years | -59.3% | -13.6% | -45.7 pts |
| 3 years | -69.6% | +14.2% | -83.8 pts |
| 5 years | -92.4% | +27.9% | -120.2 pts |
Red flags
F-score 6 of 8| serious | Negative equity Shareholders' equity is negative |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2023Sales ₹44 Cr -11.1% vs Mar 2022.
Net profit ₹2 Cr -61.3%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2016-09-16 | Annual General Meeting | |
| 2015-12-22 | Annual General Meeting | |
| 2014-12-11 | Annual General Meeting / Final Dividend - Re 0.36/- Per Share | |
| 2014-02-20 | Bonus 1:1 / Face Value Split From 10/- To Face Value 2/- | 0.1000 |
| 2013-12-03 | Annual General Meeting / Final Dividend - Rs 1.50/- Per Share (Purpose Revised) | |
| 2013-01-03 | Dividend Of Rs 1.80/- Per Share | |
| 2011-12-08 | Annual General Meeting And Dividend Rs.1.80 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Sharon Bio-Medicine Ltd?
Sharon Bio-Medicine Ltd (SHARONBIO) has a market capitalisation of Rs 39.2 Cr. at the 2019-03-28 close.
What is the P/E ratio of Sharon Bio-Medicine Ltd?
Sharon Bio-Medicine Ltd trades at a P/E of 2.06 on trailing twelve-month profit, at the 2019-03-28 close.
What were Sharon Bio-Medicine Ltd's latest quarterly results?
In the Mar 2023 quarter, Sharon Bio-Medicine Ltd sales was Rs 44 Cr (-11.1% vs Mar 2022) and net profit was Rs 2 Cr.